Identification of a Biological Signature for Schizophrenia in Serum

Institute of Biotechnology, University of Cambridge, Cambridge, UK.
Molecular Psychiatry (Impact Factor: 15.15). 04/2011; 17(5):494-502. DOI: 10.1038/mp.2011.42
Source: PubMed

ABSTRACT Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrations of 181 proteins and small molecules in 250 first and recent onset SCZ, 35 major depressive disorder (MDD), 32 euthymic bipolar disorder (BPD), 45 Asperger syndrome and 280 control subjects. Preliminary analysis resulted in identification of a signature comprised of 34 analytes in a cohort of closely matched SCZ (n=71) and control (n=59) subjects. Partial least squares discriminant analysis using this signature gave a separation of 60-75% of SCZ subjects from controls across five independent cohorts. The same analysis also gave a separation of ~50% of MDD patients and 10-20% of BPD and Asperger syndrome subjects from controls. These results demonstrate for the first time that a biological signature for SCZ can be identified in blood serum. This study lays the groundwork for development of a diagnostic test that can be used as an aid for distinguishing SCZ subjects from healthy controls and from those affected by related psychiatric illnesses with overlapping symptoms.

Download full-text


Available from: Emanuel Schwarz, Aug 26, 2015
  • Source
    • "On the other hand exposure to the non-immunoregulatory crowd infections is common in high-income urban settings. Crowd infections, such as rubella or measles, can cause inflammatory events during pregnancy that lead to fetal CNS developmental abnormalities associated with the subsequent appearance of autism and schizophrenia (extensively reviewed and referenced in Meyer et al., 2011) (Crespi and Thiselton, 2011; Schwarz et al., 2011; Zerbo et al., 2012). In fact, it may be the convergence of a lack of contact with Old Friends, together with exposure to crowd infections that has the most potential for damaging effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The immune system influences brain development and function. Hygiene and other early childhood influences impact the subsequent function of the immune system during adulthood, with consequences for vulnerability to neurodevelopmental and psychiatric disorders. Inflammatory events during pregnancy can act directly to cause developmental problems in the central nervous system (CNS) that have been implicated in schizophrenia and autism. The immune system also acts indirectly by "farming" the intestinal microbiota, which then influences brain development and function via the multiple pathways that constitute the gut-brain axis. The gut microbiota also regulates the immune system. Regulation of the immune system is crucial because inflammatory states in pregnancy need to be limited, and throughout life inflammation needs to be terminated completely when not required; for example, persistently raised levels of background inflammation during adulthood (in the presence or absence of a clinically apparent inflammatory stimulus) correlate with an increased risk of depression. A number of factors in the perinatal period, notably immigration from rural low-income to rich developed settings, caesarean delivery, breastfeeding and antibiotic abuse have profound effects on the microbiota and on immunoregulation during early life that persist into adulthood. Many aspects of the modern western environment deprive the infant of the immunoregulatory organisms with which humans co-evolved, while encouraging exposure to non-immunoregulatory organisms, associated with more recently evolved "crowd" infections. Finally, there are complex interactions between perinatal psychosocial stressors, the microbiota, and the immune system that have significant additional effects on both physical and psychiatric wellbeing in subsequent adulthood.
    Brain research 04/2014; DOI:10.1016/j.brainres.2014.04.004 · 2.83 Impact Factor
  • Source
    • "There is a certain amount of healthy skepticism in the field of psychiatry in relation to the use of biologically based diagnostic tests for schizophrenia mainly due to the fact that the VeriPsych early tests did not include tests of diagnostic specificity (schizophrenia versus other psychiatric disorders). Although this criticism was addressed by later studies from the same group [11], this diagnostic blood test for schizophrenia still did not become widely used. According to one of the developers of VeriPsych " there may have been at least two further reasons for the reluctance (1) market research found that most psychiatrists believe that they are very good at diagnosing schizophrenia patients using a basic clinical interview " [2] and (2) the $2500 (US) cost was considered high. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers have been sought after in the field of schizophrenia research for decades. In this paper, we discuss some of the concepts around developing biomarkers in an effort to understand why the use of biomarkers for schizophrenia has not been realized. In particular, we address the following 4 questions. Why would we need a diagnostic biomarker for schizophrenia? How is a biomarker typically defined and how does that influence the discovery of biomarkers in schizophrenia? What is the best use of biomarkers in schizophrenia? Do any biomarkers for schizophrenia currently exist? Thus, while we suggest that no biomarker currently exists for schizophrenia, the heterogeneity associated with schizophrenia will most likely need to be taken into account which will result in multiple biomarkers that identify the multiple underlying pathophysiological processes involved in schizophrenia. Therefore, much additional work will be required prior to obtaining any well-established biomarkers for schizophrenia.
    Disease markers 07/2013; 35(1):3-9. DOI:10.1155/2013/510402 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is an urgent necessity of designing translational strategies to schizophrenia, a mental disorder that affects 30 million people worldwide. Proteomic studies have been providing data enough to pave the way for that, but these need to be connected in a concise manner in order to translate laboratorial findings to real improvements in the lives of the patients.
    09/2012; 3(3). DOI:10.2478/s13380-012-0031-z
Show more